SCHEMBL30765489

SCHEMBL30765489

O=C(Cn1c(-c2ccccc2)ncc(NCCCCc2ccc(Oc3ccccc3)cc2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 9/20 0.39
F3 P13726 4/20 0.39
F7 P08709 3/20 0.39
NTRK1 P04629 2/20 0.38
CASP1 P29466 1/20 0.38
PRSS1 P07477 2/20 0.38
DGAT2 Q96PD7 1/20 0.37
AVPR1B P47901 1/20 0.36
CMA1 P23946 1/20 0.36
CTRC Q99895 1/20 0.36
NTRK3 Q16288 1/20 0.36
ELANE P08246 1/20 0.36
KDM6B O15054 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
NAMPT P43490 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765502 0.92 CASP1 (0.40) F2F3NTRK1CASP1PRSS1
SCHEMBL30765437 0.92 HDAC6 (0.41) F2F3F7PRSS1CMA1
SCHEMBL30765550 0.91 F2 (0.38) F2F3F7NTRK1CASP1
SCHEMBL30765634 0.90 CASP1 (0.42) NTRK1CASP1AVPR1BCMA1CTRC
SCHEMBL30765583 0.89 F2 (0.40) F2F3F7NTRK1PRSS1
SCHEMBL30765820 0.89 CMA1 (0.40) F2F3F7NTRK1PRSS1
SCHEMBL30765886 0.88 CASP1 (0.40) NTRK1CASP1AVPR1BCMA1CTRC
SCHEMBL30765470 0.88 AVPR1B (0.37) F2F3F7NTRK1CASP1
SCHEMBL30765749 0.88 F2 (0.38) F2F3F7NTRK1PRSS1
SCHEMBL30765527 0.87 NAMPT (0.44) F2F3F7NTRK1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed